| Schedule of Segment Profit or Loss |
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Lasofoxifene |
|
$ |
9,109 |
|
|
$ |
— |
|
|
$ |
17,738 |
|
|
$ |
— |
|
Fosgonimeton (ATH-1017) |
|
|
6 |
|
|
|
555 |
|
|
|
189 |
|
|
|
1,862 |
|
Brelgometon (ATH-1105) |
|
|
294 |
|
|
|
1,237 |
|
|
|
537 |
|
|
|
2,161 |
|
ATH-1020 |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
5 |
|
Preclinical programs and other costs |
|
|
465 |
|
|
|
258 |
|
|
|
820 |
|
|
|
660 |
|
Milestone liability change in fair value |
|
|
175 |
|
|
|
— |
|
|
|
(754 |
) |
|
|
— |
|
Personnel-related costs, excluding stock- based compensation |
|
|
1,859 |
|
|
|
918 |
|
|
|
3,354 |
|
|
|
1,916 |
|
Total research and development expenses |
|
|
11,908 |
|
|
|
2,968 |
|
|
|
21,884 |
|
|
|
6,604 |
|
General and administrative expenses |
|
|
4,137 |
|
|
|
2,483 |
|
|
|
10,482 |
|
|
|
6,503 |
|
Other segment expenses(a) |
|
|
3,408 |
|
|
|
1,840 |
|
|
|
4,301 |
|
|
|
3,720 |
|
Total operating expenses |
|
|
19,453 |
|
|
|
7,291 |
|
|
|
36,667 |
|
|
|
16,827 |
|
Loss from operations |
|
|
(19,453 |
) |
|
|
(7,291 |
) |
|
|
(36,667 |
) |
|
|
(16,827 |
) |
Other income, net |
|
|
446 |
|
|
|
325 |
|
|
|
1,032 |
|
|
718 |
|
Sermonix pre-funded warrant change in fair value |
|
|
— |
|
|
|
— |
|
|
|
(16,320 |
) |
|
|
— |
|
Net loss |
|
$ |
(19,007 |
) |
|
$ |
(6,966 |
) |
|
$ |
(51,955 |
) |
|
$ |
(16,109 |
) |
(a)Other segment expenses includes stock-based compensation and depreciation expenses.
|